title: Analysis of polymorphism in the survivin gene promoter as a potential risk factor for head and neck cancers development.
abstract: BACKGROUND
  Association studies have shown that gene polymorphisms in various classes of genes can modulate cancer risk. The -31G/C polymorphism in the promoter of survivin gene, affects the expression of the anti-apoptotic protein survivin which in turn may predispose an individual to some types of cancer.
  
  
  OBJECTIVE
  The aim of the study was to determine whether the survivin promoter -31G/C polymorphism could be a susceptibility factor for squamous cell carcinoma (SCC) of the oral cavity and basal cell carcinoma (BCC) of the skin.
  
  
  METHODS
  The DNA obtained from 88 patients with SCC, 60 patients with BCC and 111 healthy individuals was subjected to polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP) in order to determine genotype and allele frequencies in patients and control groups. Logistic regression was used for cancer risk assessment.
  
  
  RESULTS
  The following distribution of genotypes was obtained: CC genotype 15% in the SCC group, 13% in the BCC group and 12% in controls; CG genotype 41% in SCCs, 35% in BCCs, 48% in controls; GG genotype 44% in SCCs, 52% in BCCs and 40% in controls. Allelic frequencies were as follows: G allele 0.65 in SCCs, 0.69 in BCCs and 0.64 in the control group; C allele 0.35 in SCCs, 0.31 in BCCs and 0.36 in the control group. There was no statistically significant difference in allele or genotype frequencies between the patients and controls (p>0.05).
  
  
  CONCLUSIONS
  In Serbian population, -31G/C polymorphism in the promoter of the survivin gene cannot be considered as a risk factor for oral squamous cell carcinoma and skin basal cell carcinoma.
authors.affiliation: Institute of Human Genetics, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia. tebraceae@yahoo.com
authors.forename: Marija
authors.initials: M
authors.lastname: Kostić
authors.forename: Nadja
authors.initials: N
authors.lastname: Nikolić
authors.forename: Branislav
authors.initials: B
authors.lastname: Ilić
authors.forename: Jelena
authors.initials: J
authors.lastname: Carkić
authors.forename: Sanja
authors.initials: S
authors.lastname: Milenković
authors.forename: Miroslav
authors.initials: M
authors.lastname: Vukadinović
mesh_terms: D000368:Aged; D054458:Amplified Fragment Length Polymorphism Analysis; D051017:Apoptosis Regulatory Proteins / Q000235:genetics; D002280:Basal Cell Carcinoma / Q000235:genetics / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D006258:Head and Neck Neoplasms / Q000235:genetics; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000235:genetics / Q000473:pathology; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D012878:Skin Neoplasms / Q000235:genetics / Q000473:pathology; D000077022:Survivin
chemical_list: D051017:Apoptosis Regulatory Proteins; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin